Abstract:Background: Glioblastoma and gliosarcoma are highly aggressive, Grade IV CNS malignancies with notoriously immunosuppressive tumor microenvironments. Current standard of care involves maximal safe surgical resection, followed by radiation therapy and chemotherapy. Despite success in other cancer types, immune checkpoint inhibition (ICI) has failed to demonstrate significant efficacy in glioblastoma and gliosarcoma. We hypothesize that the generation of peripheral immune response is necessary for patients' treatment response to ICI therapy. To test this hypothesis, we are actively enrolling patients with newly diagnosed glioblastoma or gliosarcoma on a Phase 2 clinical trial where all patients receive combinatorial ICI immunotherapy (NCI-21-C-0015). Extensive monitoring of systemic immune response will allow for comparison of overall survival and outcome between patients with a peripheral blood immune response and those without. Methods: A total of 48 patients will receive combinatorial ipilimumab and nivolumab ICI therapy with adjuvant chemotherapy. Peripheral blood samples will be collected at baseline and during the course of treatment for isolation of peripheral blood mononuclear cells (PBMCs) and plasma. Patient tumor tissue will be collected as available from diagnosis and recurrence. Patients' peripheral immune response will be analyzed through immunophenotyping via high-dimensional spectral flow cytometry, multiplex cytokine and chemokine profiling of patient plasma, single cell RNA- and TCR-sequencing, and functional assays of patient T cells that include ELISpot and responsiveness to in vitro stimulation. Predictive responsiveness of patients' T cell to ICI will be evaluated with in vitro stimulation utilizing anti-CD3 Ab and CD80-Ig coupled microbeads with and without anti-CTLA-4 blocking Ab. Results of these serial assays will be compared to patients' clinical changes and overall survival to identify predictors and correlates of improved patient response and outcome. Results/Discussion: As primary endpoints have not been met for many patients and accrual is ongoing, a full analysis of clinical findings is not yet available. Thirty-two of the 48 planned patients have been enrolled onto this clinical trial. Interim analysis has been conducted and passed. Preliminary patient data analysis has confirmed feasibility of proposed methods. Twelve-plex cytokine profiling has been conducted on plasma samples from twenty-five patients and indicates unique patterns among patients, as well as differed expression compared to healthy donor samples supplied through the NIH Blood Bank. Additional patient findings are currently under analysis and will be reported at time of presentation. Citation Format: Matthew Watowich, Caitlin Huguely, Tuesday Haynes, Seiya Liu, Nasser Yaghi, Nicole Briceno, Brita Anderson, Susie Ahn, Kathleen Wall, Lily Polskin, Edina Komlodi-Pasztor, Solmaz Sahebjam, Masashi Watanabe, Mark R. Gilbert. Phase II trial evaluating the association of peripheral blood immunologic response and therapeutic response to immune checkpoint inhibition in patients with newly diagnosed glioblastoma and gliosarcoma [abstract]. In: Proceedings of the AACR Special Conference on Brain Cancer; 2023 Oct 19-22; Minneapolis, Minnesota. Philadelphia (PA): AACR; Cancer Res 2024;84(5 Suppl_1) nr A019.

Ctim-28. Neoadjuvant Anti-Pd1 Immunotherapy For Surgically Accessible Recurrent Glioblastoma: Clinical And Molecular Outcomes Of A Stage 2 Single-Arm Expansion Cohort

CTIM-25. NEOADJUVANT ANTI-PD1 IMMUNOTHERAPY FOR SURGICALLY ACCESSIBLE RECURRENT GLIOBLASTOMA: CLINICAL AND MOLECULAR OUTCOMES OF A STAGE 2 SINGLE-ARM EXPANSION COHORT

Neoadjuvant anti-PD-1 immunotherapy promotes a survival benefit with intratumoral and systemic immune responses in recurrent glioblastoma

CTIM-07. PHASE IIB RANDOMIZED, BLINDED, CONTROLLED TRIAL EVALUATING NEOADJUVANT PD-1 BLOCKADE COMBINED WITH A2B5+ GLIOMA STEM-LIKE CELL LYSATE-LOADED DCV IN RECURRENT GLIOBLASTOMA (IDH1/2 -)- TRAIL IN PROGRESS

Efficacy and safety study of neoadjuvant efineptakin alfa (NT-I7) and pembrolizumab in recurrent glioblastoma.

P3.02c-050 IMpower010: Phase III Study of Atezolizumab Vs BSC after Adjuvant Chemotherapy in Patients with Completely Resected NSCLC

PL02.3.A Survival and T-cell tumor reactivity in patients treated with nivolumab and bevacizumab for recurrent glioblastoma in the clinical trial CA209-9UP

Treatment with pembrolizumab in programmed death ligand 1–positive recurrent glioblastoma: Results from the multicohort phase 1 KEYNOTE‐028 trial

Re-irradiation plus pembrolizumab: Phase II study for recurrent glioblastoma patients

PS01.55: IMpower010: Phase III Study of Atezolizumab Vs BSC after Adjuvant Chemotherapy in Patients with Completely Resected NSCLC: Topic: Medical Oncology.

ATIM-11. TUMOR-INFILTRATING LYMPHOCYTES EXPRESSING ANTI-PD-1 ANTIBODY EXHIBIT A PROMISING EFFICACY AND SURVIVAL BENEFIT IN PATIENTS WITH RECURRENT GLIOBLASTOMA MULTIFORME

Fc-enhanced anti-CTLA-4, anti-PD-1, doxorubicin, and ultrasound-mediated blood-brain barrier opening: A novel combinatorial immunotherapy regimen for gliomas

Phase IIb Randomized, Blinded, Controlled Trial Evaluating Neoadjuvant PD-1 Blockade Combined with A2B5+ Glioma Stem-Like Cell Lysate-Loaded DC Vaccine in Recurrent Glioblastoma (IDH1/2 -).

Immune and genomic correlates of response to anti-PD-1 immunotherapy in glioblastoma

Abstract A019: Phase II trial evaluating the association of peripheral blood immunologic response and therapeutic response to immune checkpoint inhibition in patients with newly diagnosed glioblastoma and gliosarcoma

Oncolytic DNX-2401 virotherapy plus pembrolizumab in recurrent glioblastoma: a phase 1/2 trial

Ctim-23. A Phase Ii Study Of Retifanlimab (Pd-1 Inhibitor) And Epacadostat (Ido1 Inhibitor) In Combination With Bevacizumab And Hypofractionated Radiotherapy For Recurrent Glioblastoma: Nct03532295

Ctim-27. Doc1021 Cell-Based Vaccination As Adjuvant Therapy For Glioblastoma: Phase I Clinical Trial Analysis

NRG-BN002: Phase I study of ipilimumab, nivolumab, and the combination in patients with newly diagnosed glioblastoma

Preclinical investigation of combined gene-mediated cytotoxic immunotherapy and immune checkpoint blockade in glioblastoma

Combined Immunotherapy Improves Outcome for Replication-Repair-Deficient (RRD) High-Grade Glioma Failing Anti-PD-1 Monotherapy: A Report from the International RRD Consortium